HRT Financial’s Altimmune ALT Stock Holding History

HRT Financial’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-164,768	Closed	-$695K	–	2404
2023 Q1	$695K	Buy	+164,768	New	+$1.96M	0.01%	1165
2022 Q2	–	Sell	-222,368	Closed	-$1.35M	–	2875
2022 Q1	$1.35M	Buy	+222,368	New	+$1.64M	0.01%	840
2021 Q2	–	Sell	-54,557	Closed	-$770K	–	2796
2021 Q1	$770K	Buy	54,557 +43,848	+409%	+$709K	0.01%	1387
2020 Q4	$120K	Buy	+10,709	New	+$126K	﹤0.01%	1609

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HRT Financial's ALT Position: Q2 2023 in Review

HRT Financial sold out of Altimmune (ALT) in Q2 2023, closing a stake of 164,768 shares — an estimated $695K sold.

HRT Financial first reported a position in ALT in Q4 2020 and held it in 4 quarters. The position peaked at $1.35M in Q1 2022. 120 funds tracked by Wall St. Rank hold ALT as of Q2 2023.

HRT Financial reported no remaining Altimmune position as of Q2 2023 after selling out during the quarter.
HRT Financial sold 164,768 Altimmune shares in Q2 2023, an estimated $695K.
HRT Financial first reported a position in Altimmune in Q4 2020 and held it in 4 quarters.
HRT Financial's Altimmune position peaked at $1.35M in Q1 2022.
120 funds tracked by Wall St. Rank held Altimmune as of Q2 2023.

Based on HRT Financial's 13F filing for Q2 2023, filed 11 Aug 2023.